Pharma CEOs Dish on the Trump Effect

Dec 01, 2016

Reuters

Top execs from large U.S. drug companies discussed what the pharma future holds under President-elect Donald Trump, and comment on pricing issues that have cast a shadow on the industry.

Trump has said he wants to repeal Obamacare and reform Medicare and Medicaid, but he has not addressed the companies that have come under fire recently because of huge drug price increases.

Pharma companies are relieved, but Trump could be more critical of drugmakers and their price increases than the industry expects, says Allergan Inc CEO Brent Saunders, in a Reuters article.

Read the story for more pharma predictions

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments